摘要
目的探讨前瞻性分子分类工具(ProMisE)分子分型在子宫内膜癌预后评估中的应用价值。方法回顾性分析宁夏医科大学总医院收治的150例子宫内膜癌患者的临床资料,根据ProMisE分子分型将患者分为4组:DNA聚合酶ε(POLE)突变型、错配修复缺陷(MMR-d)型、p53野生(p53wt)型和p53异常(p53abn)型,比较各组患者的临床病理特征、治疗方案及预后情况。结果经ProMisE分子分型确定MMR-d型共42例(28.00%),POLE突变型共30例(20.00%),p53wt型共57例(38.00%),p53abn型共21例(14.00%),不同分子分型子宫内膜癌患者的血清CA125升高情况、肿瘤最大径、病理类型、病理分级FIGO分期情况相比,差异有统计学意义(P<0.05)。POLE突变型患者的年龄较小,肿瘤分化程度较好,预后最佳;p53abn型患者的肿瘤分期较晚,预后最差;MMR-d型和p53wt型患者的预后介于两者之间。结论ProMisE分子分型能够为子宫内膜癌患者的预后评估提供重要依据,有助于制订个体化的精准治疗方案。
Objective To explore the application value of the prospective molecular classification tool(ProMisE)molecular typing for endometrial cancer in the prognosis assessment.Methods A retrospective analysis was conducted on the clinical data of 150 patients with endometrial cancer admitted to the General Hospital of Ningxia Medical University.The patients were divided into 4 groups according to ProMisE molecular typing:DNA polymerase ε(POLE)mutant type,mismatch repair protein(MMR-d)type,p53 wild type(p53wt type)and p53 mutant type(p53abn type)were compared.The clinicopathological characteristics,treatment regimens and prognosis of patients in each group were compared.Results Endometrial cancer patients with different ProMisE molecular subtypes showed differences in age,tumor histological type,depth of myometrial invasion,lymph node metastasis,etc.,and the differences were statistically significant(P<0.05).Patients with POLE mutations are younger,have a better degree of tumor differentiation,and have the best prognosis.Patients with p53abn type have a relatively advanced tumor stage and the poorest prognosis.The prognosis of patients with MMR-d type and p53wt type lies between the two.Conclusion ProMisE molecular typing can provide an important basis for the prognosis assessment of patients with endometrial cancer and is helpful for formulating individualized and precise treatment plans.
作者
雍圆圆
雍调调
吴丽仙
YONG Yuanyuan;YONG Tiaotiao;WU Lixian(Department of Gynecology,General Hospital of Ningxia Medical University,Yinchuan,Ningxia 750004,China;Department of Emergency,General Hospital of Ningxia Medical University,Yinchuan,Ningxia 750004,China;Department of Gynecology,Cardiovascular and Cerebrovascular Disease Hospital,General Hospital of Ningxia Medical University,Yinchuan,Ningxia 750000,China)
出处
《重庆医学》
2025年第8期1877-1882,共6页
Chongqing Medical Journal
基金
宁夏医科大学校级课题(XJ2024000901)。
关键词
子宫内膜癌
ProMisE分子分型
预后评估
应用
价值
endometrial cancer
ProMisE molecular classification
prognosis evaluation
application
value
